Yo-antibodies are mainly associated with ovarian or breast cancer, DNER-antibodies with Hodgkin lymphoma (detected in 80% of patients), and mGluR1-antibodies with hematologic tumours (detected in about 30% of patients) [17]. Here, CDR2 is linked to breast cancer.